SAN DIEGO, June 4, 2018 /PRNewswire/ -- Genelux Corporation, a privately-held biopharmaceutical company focused on the
The results will be presented by lead investigator, Dr. Robert Holloway, from Florida Hospital Cancer Institute at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2018, in Chicago, IL.
"Heavily pretreated patients with late-stage platinum-resistant/refractory ovarian cancer face a poor prognosis, and would otherwise be considered for palliative care versus continuing drug therapies with diminishing clinical response," said Paul Scigalla, M.D., Ph.D., Chief Medical Officer of Genelux. "The positive results from this trial along with supporting data demonstrating mechanisms of action are therefore very encouraging. We look forward to the completion of VIRO-15."
Data from the Phase 1b trial are outlined below.
Abstract Number: 5577
Abstract Title: Phase 1b study of oncolytic vaccinia virus GL-ONC1 in recurrent ovarian cancer
Session Title/Date/Time: Gynecologic Cancer, 6/4/2018, Poster Session 1:15-4:45 PM
Abstract Highlights: The open-label, single-arm, monotherapy, dose-escalation study (https://clinicaltrials.gov/ct2/show/NCT02759588) treated eleven heavily pretreated patients (pts) with end-stage recurrent ovarian cancer (ROC). Patient characteristics include: # of prior lines: 3-4 (n=3), ? 5 (n=8); ECOG 0 (n=7) or 1 (n=4); ascites/pleural effusion (n=9); and having progressive disease at baseline (n=10). There were two dose cohorts: 3 × 109 (Cohort 1: n=6) or 1 × 1010 (Cohort 2: n=5) plaque forming units of GL-ONC1 administered per day on 2 consecutive days.
A Phase 2 trial (VIRO-15) is currently enrolling, and future studies combining GL-ONC1 and other immune therapies and/or chemotherapy are under consideration.
About GL-ONC1 GL-ONC1 is an attenuated therapeutic vaccinia virus. Clinical results in over 100 subjects treated in Genelux studies have shown GL-ONC1 is well tolerated with documented antitumor activities and clinical benefits.
About Genelux CorporationHeadquartered in San Diego, California, Genelux Corporation is a leader in oncolytic immunotherapy, utilizing its potent CHOICE™ discovery platform to develop a library of proprietary, oncolytic vaccinia virus-based diagnostic and therapeutic candidates in oncology.
For more information please visit www.genelux.com.
ContactInvestor Relationsinfo@genelux.com (909) 307-9300
View original content:http://www.prnewswire.com/news-releases/results-from-genelux-corporations-phase-1b-trial-of-gl-onc1-in-recurrent-ovarian-cancer-to-be-presented-at-the-asco-annual-meeting-2018-300658668.html
SOURCE Genelux Corporation
Subscribe to our Free Newsletters!
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...
Drug interactions checker can be used to check over the counter ( OTC) and regular prescription ...
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...View All